CYT387
Phase 2- Indications
- Myelofibrosis, primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF)
Company intelligence / Profile preview
YM BioSciences
Canadaen.wikipedia.org ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
YM BioSciences’ lead program, CYT387 (a JAK1/2 inhibitor), showed positive Phase I/II results in myelofibrosis and was advancing toward Phase III at the time of Gilead’s acquisition. Other programs included a vascular disrupting agent (CYT997) in Phase II for glioblastoma and nimotuzumab, an EGFR-targeting mAb.[1][4][6]
- Therapeutic areas
- HematologyOncology
- Modalities
- Small moleculesMonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on YM BioSciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YM BioSciences.